Discovery of Imidazopyridines as Potent Inhibitors of Indoleamine 2,3-Dioxygenase 1 for Cancer Immunotherapy.
Journal
ACS medicinal chemistry letters
ISSN: 1948-5875
Titre abrégé: ACS Med Chem Lett
Pays: United States
ID NLM: 101521073
Informations de publication
Date de publication:
11 Mar 2021
11 Mar 2021
Historique:
received:
12
01
2021
accepted:
26
02
2021
entrez:
19
3
2021
pubmed:
20
3
2021
medline:
20
3
2021
Statut:
epublish
Résumé
Indoleamine 2,3-dioxygenase 1 (IDO1) has been identified as a target for small-molecule immunotherapy for the treatment of a variety of cancers including renal cell carcinoma and metastatic melanoma. This work focuses on the identification of IDO1 inhibitors containing replacements or isosteres for the amide found in BMS-986205, an amide-containing, IDO1-selective inhibitor currently in phase III clinical trials. Detailed subsequently are efforts to identify a structurally differentiated IDO1 inhibitor via the pursuit of a variety of heterocyclic isosteres, leading to the discovery of highly potent, imidazopyridine-containing IDO1 inhibitors.
Identifiants
pubmed: 33738077
doi: 10.1021/acsmedchemlett.1c00014
pmc: PMC7958151
doi:
Types de publication
Journal Article
Langues
eng
Pagination
494-501Informations de copyright
© 2021 American Chemical Society.
Déclaration de conflit d'intérêts
The authors declare no competing financial interest.
Références
Trends Immunol. 2016 Mar;37(3):193-207
pubmed: 26839260
J Med Chem. 2016 Aug 25;59(16):7677-82
pubmed: 27509004
J Clin Invest. 2007 May;117(5):1147-54
pubmed: 17476344
ACS Med Chem Lett. 2021 Jan 28;12(2):288-294
pubmed: 33603977
Environ Sci Technol. 2015 Oct 6;49(19):11536-42
pubmed: 26327306
Proc Natl Acad Sci U S A. 2018 Mar 27;115(13):3249-3254
pubmed: 29531094
Blood. 2010 Apr 29;115(17):3520-30
pubmed: 20197554
ACS Med Chem Lett. 2017 Mar 06;8(5):486-491
pubmed: 28523098
Cancer Res. 2017 Dec 15;77(24):6795-6811
pubmed: 29247038
Nat Rev Drug Discov. 2018 Apr 27;17(5):307
pubmed: 29700490
J Med Chem. 2011 Apr 28;54(8):2529-91
pubmed: 21413808
Nat Rev Drug Discov. 2015 Sep;14(9):603-22
pubmed: 26228631
Mol Cancer Ther. 2010 Feb;9(2):489-98
pubmed: 20124451
Drug Discov Today. 2015 May;20(5):609-17
pubmed: 25478733
Mol Cancer Ther. 2021 Mar;20(3):467-476
pubmed: 33298590
Trends Immunol. 2013 Mar;34(3):137-43
pubmed: 23103127
Bioorg Med Chem Lett. 2021 Feb 1;33:127738
pubmed: 33316404
J Med Chem. 2020 Nov 12;63(21):12290-12358
pubmed: 32686940
Bioorg Med Chem Lett. 2021 Feb 1;33:127744
pubmed: 33333163
J Med Chem. 2009 Nov 26;52(22):7014-28
pubmed: 19856919